Healthcare & Pharmaceuticals

EU regulator begins rolling review of Valneva COVID-19 vaccine

1 minute read

The logo of Valneva SE is pictured at the company's headquarters in Saint-Herblain, near Nantes, France, September 13, 2021. REUTERS/Stephane Mahe

Dec 2 (Reuters) - The European Union's drug regulator said on Thursday it had started a rolling review of the inactivated-virus COVID-19 vaccine from French biotech firm Valneva (VLS.PA), weeks after the EU signed a deal with the company for supplies of the shot.

The decision to start the real-time review was based on preliminary studies that suggest the vaccine, VLA2001, triggers an antibody response against the coronavirus, the European Medicines Agency (EMA) said.

(This story corrects description to inactivated virus, in paragraph 1)

Register now for FREE unlimited access to Reuters.com
Reporting by Pushkala Aripaka in Bengaluru; Editing by Aditya Soni

Our Standards: The Thomson Reuters Trust Principles.

More from Reuters